Pharming appoints Jeroen Wakkerman as chief financial officer

,

Pharming appoints Jeroen Wakkerman as chief financial officer 

Pharming Group N.V. has appointed Jeroen Wakkerman as chief financial officer. Management says Wakkerman is an experienced CFO and finance director in multinational companies with a proven track record of financial and senior-level management in a range of industries, including overseeing implementation of company-wide ERP systems, hands-on business development, effective capital markets and M&A transactions, and successful post-acquisition integration, including U.S. entities.

He joins Pharming from Nutreco N.V., a global leader in animal nutrition and aquafeed, where he was chief financial officer for almost five years. Prior to this, Wakkerman was chief financial officer of SHV Energy N.V., finance director at Calor Gas, and has held several financial and commercial positions at Unilever and Rabobank. He is a Dutch citizen, resides in the Netherlands, and holds an MSc degree in business economics from the University of Groningen and is a chartered treasurer (UK) and a Chartered Management Accountant (UK).

“We look forward to welcoming Jeroen to Pharming during a transformational period, which has seen the company transition to a profitable biopharmaceutical business, with increasing commercial sales supporting an advancing pipeline,” says Sijmen de Vries, CEO of Pharming. “His extensive financial, operational and business development expertise will be a great asset, and significantly add to our senior management skills and experience base, as we continue to execute against our growth strategy through the development of commercial operations, pipeline assets and acquisition opportunities, supported by a future potential secondary listing in the U.S.”

Jeroen Wakkerman

“I am excited to be joining Pharming at such an important stage in the company’s development,” Wakkerman says. “Pharming has gone through an impressive journey with continually growing business results in recent years and I look forward to working with the management team and supporting colleagues across the business as the company enters its next stage of development. We are also developing rhC1INH for subsequent indications, including pre-eclampsia, acute kidney injury and we also investigating the clinical efficacy of rhC1INH in COVID-19.”